AddLife AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022
February 02, 2023 at 01:45 am EST
Share
AddLife AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2022. For the fourth quarter, the company reported sales was SEK 2,326 million compared to SEK 2,131 million a year ago. Net income was SEK 61 million compared to SEK 178 million a year ago. Basic earnings per share from continuing operations was SEK 0.5 compared to SEK 1.46 a year ago. Diluted earnings per share from continuing operations was SEK 0.5 compared to SEK 1.45 a year ago.
For the full year, sales was SEK 9,084 million compared to SEK 7,993 million a year ago. Net income was SEK 480 million compared to SEK 719 million a year ago. Basic earnings per share from continuing operations was SEK 3.96 compared to SEK 6.03 a year ago. Diluted earnings per share from continuing operations was SEK 3.95 compared to SEK 6.01 a year ago.
AddLife AB is a Sweden-based company, which is primarily involved in the healthcare industry. The Company markets and sells instruments, equipment, consumables and related services mainly to the healthcare sector. The Company operates through two segments: The LabTech segment is engaged in the sales of laboratory equipment, analytical instruments and reagents, that are used for diagnostics or biomedical research; The MedTech segment offers various medical device equipment, consumables, instruments and devices, primarily to hospitals. The Company operates through number of subsidiaries, such as BergmanLabora AB, BioNordica group, Holm & Halby A/S, Immuno Diagnostic Oy, LabRobot Products AB, Triolab-group, Active Care Sverup AB, Fenno Medical Oy, Mediplast AB, among others.
ADDLIFE AB 
